Инсулинотерапия при сахарном диабете типа 2: когда, как и чем начинать?

1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 5-е изд. Под ред. И.И.Дедова, М.В.Шестаковой. 2011.
2. Дедов И.И., Шестакова М.В. Оптимизация и интенсификация инсулинотерапии при сахарном диабете 2 типа (клинические рекомендации). Сахарный диабет (спецвыпуск). 2010; с. 9–16.
3. Дедов И.И. и др. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа. Сахарный диабет. 2011; 4: 6–17.
4. Arnolds S, Rave K, Hövelmann U et al. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. Exp Clin Endocrinol Diabetes 2010; 118 (9): 662–4.
5. Bergenstal RM, Jonson RM, Powers MA et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm to carbohydrate counting for ad-justment of mealtime insulin glulisine. Diabetes Care 2008; 31 (7): 1305–10.
6. Blonde L et al. EASD 2009. Abstract 894.
7. Bretzel RG, Nuber U, Landgraf W et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073–84.
8. Davies M, Lavalle-Gonzalez F, Storms F, Gomis R. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabeticagents:results from the ATLANTUS trial. Diabetes Obes Metab 2008; 10: 387–99.
9. Decode Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617–21.
10. Duckworth W, Abraira C, Moritz T et al (VADT Investigators). Glucose control and vascular complicationsin veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–39.
11. Fritsche A, Larbig M, Owens D, Haering H-U. Comparison between a basal-bolus and a premixed insulinregimen in individuals with type 2 diabetes–resultsof the GINGER study. Diabetes Obes Metab 2010; 12: 115–23.
12. Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367 (4): 319–28.
13. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. b-Cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012; 35 (7): 1406–12.
14. Heise T, Nosek L, Spitzer H, Heinemann L et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab 2007; 9 (5): 746–53.
15. Hermansen K, Davies M, Derezinski T et al. 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29 (6): 1269–74.
16. Holman RR, Farmer AJ, Davies MJ et al. Efficacy of Complex Insulin Regimens in Type 2 Diabetes. N Engl J Med 2009; 361: 1736–47.
17. Janka HU, Plewe G, Riddle MC et al. Comparison of basal insulin added to oral agents versus twice dailypremixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254–9.
18. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA. OPAL studygroup. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008; 10 (12): 1178–85.
19. Lee F, Znang Q, Mersey J et al. Glycemic control and cost with insulin glargine plus insulin glulisine versus premix – a randomized, prospective, observation study. Diabetologia 2008; 51 (Suppl. 1): S406.
20. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999; 42 (4): 406–12.
21. Marre M. Before oral agents fail: the case for starting insulin early. Int J Obes 2002; 26 (Suppl. 3): S25–S30.
22. Miller ME, Byington RP, Goff DC Jr et al (Action to Control Cardiovascular Risk in Diabetes Study Group). Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59.
23. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203.
24. Nicolucci A, Del Prato S, Vespassiani G. Optimizing Insulin Glargine Plus One Injection of Insulin Glulisine in Type 2 Diabetes in the ELEONOR Study. Diabetes Care 2011; 34: 2524–6.
25. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulintherapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–17.
26. Patel A, MacMahon S, Chalmers J et al (ADVANCE Collaborative Group). Intensive blood glucose controland vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72.
27. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes. A comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260–5.
28. Ratner R, Wynne A, Nakhle S et al. Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096). Diabetes Obes Metab 2011; 13 (12): 1142–8.
29. Riddle M et al. Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes. Diabetes Care 2011; 34: 2508–14.
30. Riddle MC. Timely initiation of basal insulin. Am J Med 2004; 116: 3S–9S.
31. Riddle MC, Rosenstock J, Gerich J. Treat-to Target Trial. Diabetes Care 2003; 26: 3080–6.
32. Riddle MC, Vlajnic A, Zhou R et al. HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies. Diabetes Obes Metab 2013. Mar 12; doi: 10.1111/dom.12096. [Epub ahead of print].
33. Rosenstock J, Davies M, Home PD et al. A randomised, 52 week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51 (3): 408–16.
34. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141 (6): 421–31.
35. Swinnen SG, Snoek FJ, Dain MP et al. Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes. Diabetes Technol Ther 2009; 11 (11): 739–43.
36. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
37. Wang J et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentrerandomised parallel-group trial. Lancet 2008; 371 (9626): 1753–60.
38. Wright A, Burden ACF, Paisey RB et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330–6.
39. Yki-Jarvinen H et al. Initiate Insulin by Aggressive Titration and Education (INITIATE). Diabetes Care 2007; 30: 1364–9.
40. Yki-Järvinen H, Kauppila M, Kujansuu E et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327 (20): 1426–33.
41. Yki-Järvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442–51.

Л.В.Недосугова

Кафедра эндокринологии ФППОВ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ